Allucent, a prominent global mid-sized clinical research organization (CRO), has been designated by the Biomedical Advanced Research and Development Authority (BARDA), an entity within the Administration for Strategic Preparedness and Response of the U.S. Department of Health and Human Services, to expedite the clinical research and development of next-generation COVID-19 vaccine candidates.

In the midst of the persistent challenges posed by the COVID-19 pandemic, the urgency for inventive and efficacious solutions remains paramount. Allucent plays a pivotal role as a leading clinical research organization in supporting the U.S. government's endeavors to develop medical countermeasures for emerging infectious diseases.

Through BARDA's Clinical Studies Network (CSN), Allucent will undertake a Phase IIb clinical trial involving 10,000 participants. This trial aims to evaluate the comparative effectiveness of forthcoming COVID-19 vaccine candidates in relation to authorized/approved COVID-19 vaccines for preventing symptomatic, PCR-confirmed SARS-CoV-2 infection.

Mark A. Goldberg, M.D., Chairman and CEO of Allucent, expressed the organization's honor in being selected for this significant initiative. He emphasized that the collaboration signifies a notable stride towards combating COVID-19 and its evolving variants. By utilizing their expertise and resources, Allucent aims to contribute to the development of next-generation booster vaccines that enhance global immunity and safeguard lives. Dr. Goldberg highlighted the award as a testament to their strategic focus on combating infectious diseases and expanding their portfolio of federally funded clinical trials.

The development of next-generation COVID-19 vaccines holds the potential to broaden the scope of protection against existing and future variants, prolong the duration of immunity, and offer improved safeguards against illness and transmission beyond current vaccine technologies.

This project has been made possible through funding from the U.S. Department of Health and Human Services, Administration for Strategic Preparedness and Response, Biomedical Advanced Research and Development Authority, under contract number 75A50120D00016/75A50123F33005.

Report Abuse